Ketamine Infusion Therapy: IV Protocol, What to Expect, and How It Differs from Other Forms

Ketamine has gone from an operating room anesthetic to one of the most talked-about treatments in mental health. But “ketamine therapy” means different things depending on how it’s administered. Nasal spray (Spravato), oral lozenges, intramuscular injections, and IV infusions each deliver ketamine differently, with different onset times, bioavailability, and clinical experiences.

IV ketamine infusion therapy is the original protocol that launched the field. It’s the form with the longest track record for treatment-resistant depression, and it remains the gold standard in many clinical settings. If you’re considering ketamine treatment, understanding what an IV infusion actually involves, how it differs from other delivery methods, and what the evidence supports will help you make a more informed decision.

How IV Ketamine Works in the Brain

Ketamine’s antidepressant mechanism is fundamentally different from traditional antidepressants like SSRIs or SNRIs. Understanding this helps explain why it can work when other treatments have failed.

NMDA Receptor Blockade

Ketamine is primarily an NMDA (N-methyl-D-aspartate) receptor antagonist. NMDA receptors are glutamate receptors involved in synaptic plasticity, learning, and memory. At the sub-anesthetic doses used for depression, ketamine blocks a specific population of NMDA receptors on inhibitory interneurons. This releases a burst of glutamate signaling that triggers a downstream cascade of events.

AMPA Receptor Activation

The glutamate surge from NMDA blockade activates AMPA receptors, another type of glutamate receptor. AMPA activation is critical for ketamine’s antidepressant effect. Research has shown that blocking AMPA receptors eliminates ketamine’s antidepressant properties, confirming that this step in the cascade is essential, not optional.

BDNF Release and Synaptogenesis

AMPA activation triggers the release of brain-derived neurotrophic factor (BDNF), a protein that promotes the growth and survival of neurons. BDNF activates the mTOR signaling pathway, which stimulates the formation of new synaptic connections (synaptogenesis). In animal models, a single dose of ketamine increases dendritic spine density in the prefrontal cortex within hours.

This is remarkable because chronic depression is associated with synaptic loss and reduced connectivity in the prefrontal cortex and hippocampus. Ketamine doesn’t just change neurotransmitter levels (as SSRIs do). It appears to physically rebuild neural connections that depression has degraded.

Anti-inflammatory Effects

Ketamine also has anti-inflammatory properties that may contribute to its antidepressant effect. Depression is increasingly understood as involving neuroinflammation, and ketamine has been shown to reduce inflammatory markers like IL-6 and TNF-alpha. Patients with higher baseline inflammatory markers may actually respond better to ketamine, suggesting the anti-inflammatory mechanism is clinically relevant.

The Standard IV Protocol for Depression

While protocols vary slightly between clinics, the most widely studied and commonly used IV ketamine protocol for depression follows this framework:

Initial Series

• Dose: 0.5 mg/kg of body weight, infused over 40 minutes. Some clinics adjust to 0.5 to 0.75 mg/kg based on response.
• Frequency: 6 infusions over 2 to 3 weeks (typically Monday/Wednesday/Friday for two weeks, or similar spacing).
• Setting: Clinical treatment room with comfortable recliner, dim lighting, and often calming music. Many patients use eye shades.
• Monitoring: Continuous pulse oximetry, blood pressure checks every 5 to 10 minutes, heart rate monitoring. An IV line is established before the infusion begins.
• Duration: Plan for approximately 2 hours total (pre-infusion setup, 40-minute infusion, 30 to 60 minutes of recovery before discharge).

Response Assessment

Most clinicians evaluate response after the initial 6-infusion series. Approximately 60 to 70% of patients with treatment-resistant depression experience meaningful symptom improvement. Some patients notice effects after the first or second infusion. Others don’t respond significantly until infusion 4, 5, or 6. This is why completing the full initial series is recommended before concluding that IV ketamine isn’t working.

Maintenance Phase

Ketamine’s antidepressant effect is not permanent. Without maintenance, symptoms typically return within weeks to months. The maintenance schedule varies by individual:

• Some patients do well with monthly infusions.
• Others need biweekly sessions initially, gradually spacing to monthly or less frequent.
• Some clinics transition patients to oral ketamine (lozenges or troches) for at-home maintenance between infusions.
• The goal is to find the minimum effective frequency that keeps symptoms managed.

What the Experience Feels Like

This is often the biggest source of anxiety for people considering IV ketamine. Here’s what most patients report:

During the Infusion (0 to 40 minutes)

Onset (5 to 10 minutes): Effects typically begin within the first 5 to 10 minutes. You may notice a sense of lightness, mild floating, or a subtle shift in how things look or sound.

Peak dissociation (15 to 30 minutes): At the standard 0.5 mg/kg dose, most patients experience moderate dissociation. This is not unconsciousness. You remain aware but your sense of self and body feels altered. Common descriptions include:

• Feeling like you’re floating or disconnected from your body
• Visual distortions (colors seem brighter, surfaces may appear to ripple or breathe)
• Time distortion (40 minutes can feel like 10 or like 2 hours)
• A sense of emotional openness or introspection
• Occasionally, a feeling of profound calm or transcendence

Nausea: Some patients experience nausea during the infusion. Most clinics pretreat with ondansetron (Zofran) if needed. Keeping your eyes closed and remaining still reduces motion-triggered nausea.

Recovery Phase (40 to 90 minutes post-infusion)

After the infusion stops, dissociative effects taper over 30 to 60 minutes. You may feel groggy, mildly euphoric, or emotionally tender. Coordination and reaction time are impaired during this period, which is why you cannot drive yourself home. Most clinics require a designated driver or ride service.

By 2 to 4 hours post-infusion, most patients feel essentially normal, though some report mild fatigue or heightened emotional sensitivity for the rest of the day.

Who Administers IV Ketamine?

The medical professionals most commonly administering IV ketamine include:

• Anesthesiologists: Ketamine is an anesthetic drug, and anesthesiologists have the deepest familiarity with its pharmacology, dosing, and management of potential complications. Many ketamine clinics are founded by anesthesiologists.
• Psychiatrists: Particularly those with training in procedural psychiatry or interventional psychiatry. Psychiatrists bring the advantage of being able to manage the mental health component alongside the infusion.
• CRNAs (Certified Registered Nurse Anesthetists): Qualified to administer anesthesia and monitor patients during infusions. CRNAs work in many ketamine clinics, often under physician supervision.
• Emergency medicine physicians: Some ER physicians have transitioned to ketamine practice, given their extensive experience with the drug in emergency settings.

The key qualification isn’t the specific credential. It’s that the provider has appropriate training in ketamine administration, vital sign monitoring, airway management (rare but critical if needed), and screening for contraindications.

Comparison of Ketamine Delivery Methods

When to Choose IV Ketamine vs. Other Forms

IV infusion is usually the best choice when:

• You want the highest bioavailability and most precise dose control.
• You have treatment-resistant depression and want the delivery method with the most clinical evidence.
• Your provider recommends it based on your clinical profile.
• You can afford the out-of-pocket cost.
• You want the ability to adjust the dose in real-time during the infusion based on your response.

Spravato (esketamine) may be preferable when:

• Insurance coverage is a deciding factor. Spravato is FDA-approved and covered by many plans.
• You prefer a non-IV route but still want a clinically monitored experience.
• Your psychiatrist is part of the REMS (Risk Evaluation and Mitigation Strategy) certification program.

Oral/sublingual ketamine may work when:

• You’ve responded well to IV or IM ketamine and need a lower-cost maintenance option.
• Clinic visits are difficult due to distance or scheduling.
• Your provider has established the right dose through prior in-clinic treatments.
• You understand the lower and more variable bioavailability.

IM injection may be appropriate when:

• IV access is difficult (poor veins).
• You want high bioavailability without the need for an IV line.
• The clinic offers IM as a standard protocol (some psychedelic-assisted therapy models prefer IM).

What IV Ketamine Treats (and What It Doesn’t)

Strong Evidence

• Treatment-resistant depression (TRD): The most studied indication. Multiple randomized controlled trials show rapid antidepressant effects, often within hours to days.
• Suicidal ideation: Ketamine reduces suicidal thoughts rapidly, often within hours. This is one of the most compelling aspects of ketamine therapy, as traditional antidepressants take weeks to work and carry their own suicidality warnings during the initial period.

Moderate Evidence

• Bipolar depression: Several studies show ketamine is effective for depressive episodes in bipolar disorder, though careful monitoring is needed to avoid triggering mania.
• PTSD: Growing evidence suggests ketamine can reduce PTSD symptoms, possibly through its effects on fear memory reconsolidation and default mode network activity.
• Chronic pain: Higher doses and longer infusion protocols (sometimes multi-day) are used for chronic pain conditions including CRPS, neuropathic pain, and fibromyalgia. This is a different protocol than the depression protocol.
• OCD: Preliminary studies show short-term symptom reduction, though the effects may not last as long as they do for depression.

Limited or Insufficient Evidence

• Generalized anxiety disorder (some positive signals, few rigorous studies)
• Eating disorders (very early research)
• Substance use disorders (promising but preliminary)

Safety, Side Effects, and Contraindications

Insurance and Cost Reality

This is often the biggest barrier to IV ketamine treatment. Here’s the financial reality:

IV ketamine: $400 to $800 per infusion. A standard 6-infusion initial series costs $2,400 to $4,800. Maintenance infusions add ongoing cost. Most insurance plans do not cover IV ketamine for depression because it is an off-label use (ketamine is FDA-approved only as an anesthetic, not an antidepressant).

Spravato (esketamine): The list price is high ($600 to $900 per session), but because it has FDA approval for treatment-resistant depression, many insurance plans cover it with prior authorization. Your out-of-pocket cost with insurance may be $0 to $150 per session. Janssen (the manufacturer) also offers a savings program.

Some IV ketamine clinics offer financing plans or package discounts. A few progressive insurance plans have started covering IV ketamine on a case-by-case basis, particularly after documented failure of multiple other treatments. Always ask your clinic about insurance advocacy and appeal processes.

Finding a Qualified Provider

The ketamine therapy space has grown rapidly, and not all clinics meet the same standards. When evaluating a provider, consider:

• Medical credentials: The administering provider should be a physician (MD/DO), CRNA, or nurse practitioner with specific training in ketamine administration.
• Monitoring equipment: At minimum, continuous pulse oximetry, blood pressure monitoring, and cardiac monitoring should be available. Emergency airway equipment should be on site.
• Mental health integration: The best outcomes occur when ketamine infusions are combined with psychotherapy (either during the infusion or between sessions). Look for clinics that either provide integrated therapy or coordinate closely with your existing mental health provider.
• Screening process: A thorough intake should include psychiatric history, medication review, medical history (cardiovascular, hepatic, urological), substance use history, and discussion of expectations and treatment goals. Walk away from any clinic that seems to skip this step.
• Follow-up protocols: Good clinics don’t just administer infusions and send you home. They have structured follow-up, symptom tracking, and clear criteria for adjusting your treatment plan.

References

1. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. doi:10.1016/s0006-3223(99)00230-9
2. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. doi:10.1001/archpsyc.63.8.856
3. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142. doi:10.1176/appi.ajp.2013.13030392
4. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-964. doi:10.1126/science.1190287
5. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238-249. doi:10.1038/nm.4050
6. Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175(2):150-158. doi:10.1176/appi.ajp.2017.17040472
7. Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681-688. doi:10.1001/jamapsychiatry.2014.62
8. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399-405. doi:10.1001/jamapsychiatry.2017.0080

Related Reading

• Ketamine Therapy: The Complete Guide
• Ketamine for Depression: What the Research Shows
• Psychedelic Therapy for Depression
• Psilocybin Therapy: A Complete Guide
• Biofeedback for Anxiety: How It Works